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This study compared levetiracetam (Keppra®) with reference antiepileptic drugs (AEDs) in the rat pilocarpine model of temporal
lobe epilepsy. Electroencephalogram (EEG) recordings showed that i.p. administration of valproate (300 mg/kg), phenobarbital
(5 mg/kg) and clonazepam (0.5 mg/kg) all significantly delayed the appearance of the first epileptic spike discharge in hippocam-
pus as well as synchronous epileptiform activity in hippocampus and cortex. In contrast, i.p. administration of levetiracetam
(17 mg/kg) only significantly delayed the appearance of the latter. This was corroborated by findings showing that i.p. administra-
tion of levetiracetam (17 mg/kg) significantly opposed pilocarpine-induced increases in the amplitude of the orthodromic popu-
lation spike in the hippocampal CA3 area of urethane-anaesthetised rats, while valproate (200 mg/kg), phenobarbital (10 mg/kg)
and clonazepam (1 mg/kg) had no effect. Pre-treatment i.p. with phenobarbital (10 mg/kg) and clonazepam (0.5 mg/kg) sig-
nificantly reversed seizure-induced changes in aspartate and GABA concentrations while valproate (300 mg/kg) significantly
reduced aspartate concentrations further. In contrast, levetiracetam (34 mg/kg) significantly counteracted all seizure-induced
alterations in amino acid concentrations. Midazolam induced significant seizure protection after microinjection into substantia
nigra pars reticulata (SNR, 50 nmol), nucleus accumbens (NA, 25 nmol) and caudate putamen (CP, 25 nmol), whereas phenytoin
(50 nmol) only showed significant seizure protection after injection into the latter area. Levetiracetam differed by significant
seizure protection after injection into SNR (1000 nmol) and NA (3000 nmol). These results suggest that levetiracetam is distinct
from other AEDs by its ability to selectively suppress synchronisation of neuronal spike and burst firing in hippocampus.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Seizures induced by systemic administration of pilo-
carpine to rats have a focal limbic onset, and thereby
mimic complex partial seizures with secondary
generalisation in man1. Systemic administration of
GABAergic antiepileptic drugs (AEDs) (benzodi-
azepines and barbiturates) suppress seizures in this
model2. Blockers of Na+ channels (carbamazepine
and phenytoin) are inactive and the T-type Ca2+
channel blocker ethosuximide increases the suscepti-
bility to these seizures. The same profile is observed
after intranigral microinjection3 and correlates with
the ability of these drugs to alter firing in GABAergic
neurones in substantia nigra pars reticulata (SNR)4.
This suggests a selective action of GABAergic drugs
in this model involving an ability to directly suppress
neuronal activity in the GABAergic projections from
SNR.
Levetiracetam (LEV; Keppra®) is a novel AED
that previously has been reported to suppress
pilocarpine-induced seizures in both mice and rats
after systemic administration5. The mechanism of
action of LEV appears unrelated to any modulation
of voltage-activated Na+ and low-voltage-activated
(T-type) Ca2+ channels6. A substantial number of
studies have also reported that LEV is devoid of any
conventional effects on the GABAergic system7–10.
Instead, LEV appears associated with several novel
mechanisms involving a moderate reduction in the
high-voltage-activated Ca2+ current11 and a modest,
partial inhibition of the delayed rectifier K+ current12.
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Another effect may relate to an ability to oppose
the inhibitory action of several negative allosteric
modulators on ionotropic inhibitory receptors9.
The ability of LEV to suppress pilocarpine-induced
seizures in both mice and rats appears to contrast
the lack of evidence for any direct facilitation of
GABAergic inhibition. This stimulated the present
study to characterise electrophysiological and neuro-
chemical effects of LEV on main excitatory and in-
hibitory neurotransmitters in the rat pilocarpine model
and to compare with the action of GABAergic AEDs.
Another part of this study was devoted to identify
brain areas involved in LEV’s seizure protection and
to compare with the profile of classical AEDs having
either GABAergic or Na+ channel blocking effects.
MATERIAL AND METHODS
Animals
Adult male Sprague–Dawley rats weighing 300–350 g
were used. The animals were kept on a 12/12 hour
light/dark cycle with light on at 06:00 hour and were
housed at a temperature maintained at 20–21 ◦C and
at a humidity of about 40%. All animals had free ac-
cess to standard pellet food and water before random
assignment to experimental groups.
Pilocarpine-induced seizure activity
The rats were pre-treated with methyl-bromoscopol-
amine (1 mg/kg s.c.) 30 minutes before administra-
tion of pilocarpine. The dose of pilocarpine selected
(375 mg/kg i.p.) was a CD97 dose for the induction
of secondarily generalised seizures (stage 3, 4 and 5
seizures, see the following description) in 97% of the
animals5. After administration of pilocarpine, the con-
vulsive behaviour was scored in experiments involv-
ing awake animals according to Racine13 where 0 =
no reaction; 1 = stereotype mouthing, eye blinking
and/or mild facial clonus; 2 = head nodding and/or
severe facial clonus; 3 = myoclonic jerks in the fore-
limbs; 4 = clonic convulsions in the forelimbs with
rearing and 5 = generalised clonic convulsions asso-
ciated with loss of balance.
Electroencephalogram (EEG) recordings
The animals were implanted with an electrode in
right hippocampus and three cortical electrodes
(frontal left and occipital right and left). The AEDs
were administered i.p. at optimal pre-treatment times
at their minimum active dose against secondarily
generalised motor seizures induced by pilocarpine
in rats (LEV at 17 mg/kg i.p. −60 minutes; val-
proate at 300 mg/kg i.p. −15 minutes; clonazepam at
0.5 mg/kg i.p. −30 minutes; phenobarbital at 5 mg/kg
i.p. −30 minutes)5. Immediately after pilocarpine
administration, EEG recordings were started and per-
formed for 120 minutes. The time to onset of the first
isolated spike and burst discharge in hippocampus,
the first three synchronous episodes of a fluctuat-
ing signal (waxing and waning) in hippocampus
together with an isoelectric signal in cortex and the
first burst of at least 4 seconds with a minimum fre-
quency of 8 Hz in both hippocampus and cortex were
determined (Fig. 1).
Extracellular field potentials in
the hippocampal CA3 area
Our methodology of extracellularly recording field
potentials in the hippocampal CA3 area of urethane-
anaesthetised rats has previously been described14.
The characteristic field potential, elicited in the
CA3 area by commissural stimulation, is known15
to consist of two population spikes (PS): a shorter
latency antidromic (i.e. non-synaptic) PSanti and a
longer (>3 ms) latency orthodromic PSortho (see ex-
ample of response in Fig. 2). Evoked field potentials
were recorded before the injection of pilocarpine
and then repeated three times, starting at 30, 60 and
100 minutes after pilocarpine administration. The
acquisition software averaged on-line three succes-
sive samples of field potentials, evoked at 20-second
intervals, and calculated the amplitudes (and laten-
cies) of PS. The amplitude of each PS was measured
from the negative peak to a tangent drawn between
the preceding and the following maxima of the
waveform. The response of each animal was consis-
tently expressed by the amplitude of the orthodromic
(i.e. trans-synaptic) PS, Psortho, elicited with stimuli
of 1 mA.
Amino acid concentrations in hippocampus
Immediately following pilocarpine administration,
motor seizures were observed. Groups of rats were de-
capitated after 15 minutes with partial (focal) seizures,
other groups after partial seizures followed by sec-
ondary generalisation for 30 minutes. Hippocampus
were removed on an ice-chilled plate, frozen in liquid
nitrogen and weighed. Tissue was homogenised in
a 0.1 mol/l solution of HClO4 containing EDTA
300µmol/l and heparin (150 IU/ml) in a proportion
of 8µl/mg tissue. The samples were then centrifuged
at 1200 × g (4 ◦C) for 15 minutes. The supernatant
was used for HPLC determination of amino acids
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Fig. 1: Epileptiform EEG activity induced by systemic administration of pilocarpine (375 mg/kg i.p.) to rats. (A) First epileptic
spike discharge in hippocampus; (B) first epileptic burst discharge in hippocampus; (C) synchronous ‘waxing and waning’ firing
in hippocampus and isoelectric signal in cortex; (D) synchronous, continuous and generalised burst firing in hippocampus and
cortex. Hp: hippocampal derivation, Fr.Oc.CX: fronto-occipital and cortical derivation; Oc.CX: bioccipital and cortical derivation.
known to act as main excitatory (aspartate) or in-
hibitory (glycine, GABA) neurotransmitters or to be
involved in the metabolism of the latter (glutamine)
using fluorescence detection following precolumn
derivatisation (AccQ.Tag Method—Waters).
Fig. 2: Effect of pilocarpine (PILO, 375 mg/kg i.p.) on the
amplitude of orthodromic PSortho, evoked in CA3 area of
urethane-anaesthetised rats, upon constant-current (1 mA)
commissural stimulation. Representative records of field
potentials (averages of three successive samples, at
20-second intervals) evoked in the same rat before (trace
at left) and 30 minutes after PILO (trace at right). The scale
bars apply to both traces.
Microinjection of AEDs into specific brain areas
Infusions were performed bilaterally in unanaes-
thetised rats 12–14 days after implantation of guide
cannulas. The drugs were delivered in a volume
of 1µl at a rate of 0.5µl/minute to SNR, caudate
putamen (CP) and nucleus accumbens (NA). Fif-
teen minutes prior to pilocarpine administration,
LEV (10 nmol–3µmol), midazolam (10–50 nmol)
or phenytoin (10–50 nmol) were microinfused for
2 minutes. After observation for the motor seizures,
the brain of the animals were removed and histologi-
cally examined for correct implantation.
Drugs
LEV was synthesised in the chemical laboratories
of UCB. Together with pilocarpine hydrochloride
(Sigma), methyl-bromoscopolamine (Sigma), sodium
valproate (Sigma), midazolam (Hoffman-La Roche),
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sodium phenobarbital (Federa) and sodium pheny-
toin (RBI), all these compounds were dissolved in
0.9% saline. Clonazepam (Hoffman-La Roche) was
suspended in 0.9% saline containing 0.1% Tween 80.
Statistical analysis
A Kolmogorov–Smirnov test was applied for de-
termining the significance of differences on EEG
parameters between control and treated groups. A
paired t-test was used for determining the signifi-
cance of time-related changes in pilocarpine-induced
alterations in the amplitude of PSortho within both
the control and treated groups, whereas comparisons
between control and treated groups were performed
with an unpaired t-test. An unpaired t-test was also
applied for determining the significance of differ-
ences in alterations in amino acid concentrations in
hippocampus, both with respect to comparisons be-
tween control, partial and generalised seizure groups
as well as with respect to comparisons between con-
trol and treated groups. A Fisher test (one tailed) was
applied for determining the significance of difference
between control and treated groups in the percentage
of animals showing secondarily generalised seizures
after microinfusion into specific brain areas. In all
experiments, differences were considered statistically
significant when P < 0.05.
RESULTS
EEG recordings
Valproate, clonazepam and phenobarbital all signifi-
cantly delayed both the appearance of the first epilep-
tic spike discharge in hippocampus and synchronous
epileptiform activity (waxing and waning, isoelectric
signal and burst firing) in hippocampus and cortex
(Table 1). In contrast, LEV only significantly delayed
the appearance of the latter.
Extracellular field potentials in
the hippocampal CA3 area
Pilocarpine increased the amplitude of PSortho,
evoked in CA3 area by constant-current commissural
stimulation, in a time-dependent manner (Fig. 2).
Pilocarpine-induced increase in PSortho amplitude
was nearly eliminated by pre-administration of
LEV (Fig. 3). The data in Table 2 show that the
pilocarpine-induced increase in PSortho amplitude
was significantly lower in the group pre-treated with
LEV. In contrast, only a trend was observed with
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Fig. 3: Time-course of pilocarpine (PILO, 375 mg/kg i.p.)-induced changes in the amplitude of PSortho, evoked upon 1 mA
commissural stimulation, recorded in urethane-anaesthetised (control) rats and in urethane-anaesthetised rats receiving
levetiracetam 17 mg/kg i.p. (LEV-treated), 60 minutes before pilocarpine. The bars represent mean± SEM (N = 6). Significant
(P < 0.05) differences with respect to the pre-pilocarpine level, assessed with paired t-test, are indicated with asterisk (∗).
clonazepam, and valproate and phenobarbital had no
effect.
Amino acid concentrations in hippocampus
Secondary generalised seizures generally induced
more marked alterations in the amino acid concentra-
tions of excitatory and inhibitory neurotransmitters
than partial seizures (Fig. 4). Significant reductions in
aspartate and increases in glutamine and GABA levels
were observed. In contrast, glycine levels remained
unchanged.
Treatment with phenobarbital and clonazepam
significantly reversed the changes in aspartate and
GABA levels (increase in aspartate and reduction in
GABA) observed after pilocarpine-induced secondary
Table 2: Effects of levetiracetam, phenobarbital, valproate and clonazepam on pilocarpine-induced increase in amplitude of the
orthodromic PSortho, evoked in CA3 area of urethane-anaesthetised rats, upon constant-current (1 mA) commissural stimulation.
Treatment 30-minute post-PILO 60-minute post-PILO 100-minute post-PILO
Saline 1.61 ± 1.40 2.29 ± 1.70 2.32 ± 1.65
Levetiracetam (17 mg/kg i.p., 60 minutes before PILO) −0.08 ± 1.04∗ 0.17 ± 1.52∗ 0.22 ± 1.30∗
Saline 1.08 ± 0.99 1.50 ± 1.17 1.63 ± 0.73
Valproate (200 mg/kg i.p., 20 minutes before PILO) 1.14 ± 1.16 1.31 ± 1.39 1.34 ± 1.35
Phenobarbital (10 mg/kg i.p., 60 minutes before PILO) 1.43 ± 1.44 1.77 ± 1.62 1.49 ± 1.81
Vehicle 0.73 ± 0.79 1.44 ± 1.09 1.41 ± 1.27
Clonazepam (1 mg/kg i.p., 60 minutes before PILO) 0.73 ± 1.18 1.03 ± 1.07 0.79 ± 1.43
The values, expressed in mV, represent mean± SD (N = 6 rats per group) of the differences between the amplitude of PSortho, measured
in the same animal at different times after pilocarpine 375 mg/kg i.p. (PILO) and the amplitude measured before PILO. Significant
(P < 0.05) differences between the treated group and the paired control group, assessed with t-test, are indicated with asterisk (∗).
generalised seizures whereas valproate only revealed
a significant ability to further reduce aspartate levels
(Fig. 5). In contrast, LEV significantly reversed all
alterations induced by secondary generalised seizures
by increasing aspartate and reducing glutamine and
GABA levels. In addition, a minor, but significant,
reduction was also observed in the glycine levels that
was unaffected by the pilocarpine-induced secondary
generalised seizures.
Microinjection of AEDs into specific brain areas
Midazolam protected significantly against secondar-
ily generalised seizures induced by pilocarpine after
infusion into both SNR, CP and NA (Table 3). Pheny-
toin only showed significant seizure suppression after
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Fig. 4: Alteration in amino acid concentrations in
hippocampus after partial and secondarily generalised
seizures induced by systemic administration of pilocarpine
(375 mg/kg i.p.) to rats. Concentrations are reported as
mol/g of wet tissue (mean± SD). The significance of
differences with respect to the control group or the partial
seizures group, assessed with a t-test, are indicated with
(∗) and (•), respectively. Statistical significance: ∗ •P <
0.05, ∗∗ ••P < 0.01, ∗∗∗ •••P < 0.001.
infusion into CP. In contrast, LEV revealed significant
seizure protection after infusion into SNR and NA.
DISCUSSION
The CA3 area has been known for long to be the
hippocampal region where epileptiform bursting
originates16. The pilocarpine-induced increase in the
amplitude of the orthodromic PS in this brain region
indicates that pilocarpine entailed a larger number of
neurones to fire simultaneously (neuronal synchrony).
Our results suggest that LEV opposes this increase in
neuronal synchrony in the hippocampus. This corrob-
orates previous in vitro17 and in vivo14 observations
showing that LEV reduces epileptiform increases in
the PS amplitude in other rat models of epilepsy. In
contrast, clonazepam only revealed a trend to oppose
this marker of the epileptiform effect of pilocarpine,
and valproate and phenobarbital did not oppose it at
all.
EEG analysis of seizures induced by systemic
administration of pilocarpine to rats suggests a hip-
pocampal origin of epileptic activity, starting with
isolated neuronal spike discharges which progresses
into burst firing that finally increases in intensity and
then propagates to cortex1. Pre-treatment with LEV
and GABAergic AEDs in comparative doses, i.e. the
lowest effective dose giving a significant protection
against secondary generalised seizures5, revealed
a particular type of electrographic action of LEV
against pilocarpine-induced seizures. In contrast to
the effect of GABAergic AEDs, LEV did not inter-
fere with the onset of neuronal spike and burst firing
in hippocampus, but inhibited sufficient synchronisa-
tion for their propagation to cortex. Likewise, LEV
opposed the neuronal synchronisation reflected in
the pilocarpine-induced increase in the amplitude of
the orthodromic PS in CA3, while the GABAergic
AEDs were inactive. It should be noted that the
experimental conditions of the EEG and extracellu-
lar field potential recordings differ markedly by the
former being conducted in awake and the latter in
urethane-anaesthetised rats. This prevents any direct
comparison of similar dose levels. Despite this lim-
itation, the findings in both models suggest that the
observed inhibition by LEV of seizure propagation
from hippocampus to cortex relates to an interfer-
ence with synchronisation of epileptiform activity.
Thus, the seizure protection afforded by LEV against
pilocarpine-induced secondary generalised motor
seizures may involve a selective ability to prevent
synchronisation of neuronal discharges deriving from
hippocampus and thereby their propagation to cortex.
These findings confirm previous in vitro18 and
in vivo19 recordings from the CA3 hippocampal area
showing that LEV interferes with neuronal burst fir-
ing induced by synaptic activation in the presence
of the chemoconvulsant bicuculline, without altering
normal neuronal excitability. Indeed, a recent in vitro
study on epileptiform responses induced by a ‘high
K+–low Ca2+’ perfusion fluid in the CA3 hippocam-
pal area of slices suggested that LEV is distinct
from classical AEDs by its ability to inhibit neu-
ronal hypersynchronisation17. This selective ability
of LEV to prevent synchronisation of neuronal spike
and burst firing without affecting normal neuronal
excitability may also explain both its lack of anticon-
vulsant activity against acute seizures with immediate
ictal activity induced by a maximal electroshock or
maximal CD97 doses of different chemoconvulsants,
as well as its significant safety margin in rodents5.
The pattern of pilocarpine-induced alterations in
hippocampal amino acid concentrations of known
excitatory and inhibitory neurotransmitters observed
in the present study confirms previous reports20, 21.
Although the pharmacological effect of the AEDs in
general was modest, LEV, phenobarbital and clon-
azepam appear to contrast valproate in their action
against pilocarpine-induced alterations in amino acid
concentrations. Indeed, these three AEDs induced a
similar pattern consisting of elevation of aspartate
levels and reductions in GABA levels. Likewise, LEV
also significantly reduced the enhanced glutamine
levels following pilocarpine-induced seizures. Taken
together, these results suggest that LEV induced a
more marked normalisation of pilocarpine-induced
changes in hippocampal concentrations of neurotrans-
mitters than other AEDs which may be associated
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Fig. 5: Effects of LEV and reference AEDs on the alteration in amino acid concentrations in hippocampus after secondarily
generalised seizures induced by systemic administration of pilocarpine (375 mg/kg i.p.) to rats. The control rats were sacrificed
after partial seizures followed by secondarily generalised seizures for 30 minutes (approximately 50 minutes after
administration of pilocarpine). The drug-treated animals only developed partial seizures and were sacrificed 50 minutes after
administration of pilocarpine. Concentrations are reported as mol/g of wet tissue (mean± SD). The reported data represent
individual experiments comparing controls (N = 10) to LEV (34 mg/kg i.p. 60 minutes before PILO, N = 12); controls (N = 9)
to phenobarbital (PB; 10 mg/kg i.p. 30 minutes before PILO, N = 9); controls (N = 9) to clonazepam (CZP; 0.5 mg/kg
i.p. 30 minutes before PILO, N = 13) and controls (N = 13) to valproate (VAL; 300 mg/kg i.p. 15 minutes before PILO, N =
14). Significant differences (P < 0.05, P < 0.01, P < 0.001) with respect to the control group, assessed with a t-test, are
indicated with asterisks (∗), (∗∗) and (∗∗∗), respectively.
with its ability to counteract synchronisation of neu-
ronal spike and burst firing in hippocampus.
Systemic administration of pilocarpine to rats in-
duces motor seizures which are selectively suppressed
by systemic and intranigral injection of AEDs which
modulate GABAergic neurotransmission3. Although
there is no consistent evidence to support direct effect
on the GABA system, LEV also protects against these
seizures after both systemic and intranigral injection.
This is consistent with a recent report showing that
LEV reduces spontaneous neuronal firing in SNR
of anaesthetised rats after systemic administration22.
The same paper suggested that marked reductions
in striatal GABA turnover induced by LEV disin-
hibits the GABAergic pathway from striatum to SNR
sufficiently to induce significant reductions in the
neuronal activity of the GABAergic projections from
the SNR. Indeed, it has been proposed that a deficit in
GABA-mediated inhibition in the striatum disinhibits
GABAergic striatal output pathways to SNR and
thereby enhances inhibition in SNR and propagation
of seizure activity22. Interestingly, the present study
showed that direct microinjection of LEV into the
SNR also induces seizure protection. This suggests
that LEV might reduce SNR neuronal firing by both
indirect and direct effects.
Our findings revealed an area-specific action of
LEV against pilocarpine-induced motor seizures that
appears to differ both from that of benzodiazepine
ligands (midazolam) and from that of Na+ channel
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Table 3: Effects of LEV and reference AEDs against pilocarpine-induced seizures (375 mg/kg i.p.) in rats after microinfusion
into specific brain areas.
Treatment Dose (nmol) Incidence of generalised seizures (%)
SNR CP NA
LEV 0 100 75 80
10 57 50 83
100 71 57 43
1000 33 ∗ 50 20
3000 29 ∗ 43 0 ∗
Midazolam 0 83 88 80
10 71 60
25 75 14 ∗ 0 ∗
50 22 ∗ 0 ∗ 0 ∗
Phenytoin 0 86 88 100
10 57 50
25 100 33 60
50 100 25 ∗
100 57
Compounds were microinfused 15 minutes prior to pilocarpine administration and the rats were scored for severity of motor seizures
during 2 hours. Values given are the percentage of animals showing secondarily generalised seizures (N = 4–10 per group). Significant
(P < 0.05) differences with respect to the control group, assessed with a Fisher test, are indicated with asterisk (∗).
blockers (phenytoin). In that respect, the seizure
protection of LEV after infusion into a sub-area of
striatum (NA) is interesting. Several studies have re-
ported that focal injection of various non-GABAergic
ligands into striatum induces protection against
pilocarpine-induced motor seizures in rats23–25. This
suggests that the modulation by LEV in situ of neu-
ronal firing in GABAergic projections from the SNR
partly may involve activation or inhibition of neuro-
transmitter systems deriving from other brain areas
than the SNR, in particular from striatum, and partly
from a direct action on SNR.
In summary, the present study demonstrates that the
seizure protection afforded by systemic administration
of LEV against pilocarpine-induced motor seizures
in rats is distinct from GABAergic AEDs by involv-
ing a selective inhibition of synchronisation of neu-
ronal spike and burst firing in the hippocampus. This
may relate to an ability to reverse pilocarpine-induced
alterations in hippocampal concentrations of aspar-
tate, glutamine and GABA as well as to a reduc-
tion in glycine levels, the latter being unaffected by
seizure activity. Like GABAergic drugs, LEV induced
seizure suppression after intranigral injection but re-
vealed an area-specific seizure protection which dif-
fers from both GABAergic and Na+ channel blocking
AEDs. Taken together, these results suggest a novel
mode of action of LEV in the rat pilocarpine model
of temporal lobe epilepsy.
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